{"id":"NCT02581410","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-15","primaryCompletion":"2016-08-30","completion":"2017-08-01","firstPosted":"2015-10-21","resultsPosted":"2017-09-26","lastUpdate":"2018-08-28"},"enrollment":430,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)","otherNames":[]}],"arms":[{"label":"GSK1437173A Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.","primaryOutcome":{"measure":"Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations","timeFrame":"One month after dose 2, at Month 3","effectByArm":[{"arm":"GSK1437173A Group","deltaMin":50522.9,"sd":null},{"arm":"Control Group","deltaMin":48589.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":32,"countries":["United States"]},"refs":{"pmids":["32103273","29029122"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":215},"commonTop":["Pain","Fatigue","Erythema","Headache","Myalgia"]}}